Acumen Pharmaceuticals, Inc. (ABOS) vs Precision BioSciences, Inc. (DTIL)
A side-by-side comparison of Acumen Pharmaceuticals, Inc. and Precision BioSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ABOS
Acumen Pharmaceuticals, Inc.
$2.06HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
DTIL
Precision BioSciences, Inc.
$6.30HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — ABOS vs DTIL
growth of $100 · dividends reinvested · last 5yABOS -89.4% (-36.2%/yr)DTIL -98.3% (-55.9%/yr)ABOS compounded faster over this window
Log scale — wide-divergence pair
ABOS DTIL
ABOS vs DTIL: by the numbers
- •DTIL is the larger company ($174M vs $149M market cap).
- •Both run net losses; ABOS's is the smaller (0.00% vs -117.04% net margin).
Metrics side by side
Valuation
| Metric | ABOS | DTIL |
|---|---|---|
| P/S ratio | N/A | 3.86 |
| P/B ratio | 2.60 | 3.84 |
Profitability
| Metric | ABOS | DTIL |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -152.19% |
| Net margin | 0.00% | -117.04% |
| ROE | -183.44% | -116.42% |
| ROIC | -118.67% | -30.23% |
Growth (annualized)
| Metric | ABOS | DTIL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.13% |
| Total return CAGR (5Y) | -32.60% | -54.84% |
Frequently asked
- How have ABOS and DTIL total returns compared?
- Over the past 5 years, ABOS delivered -32.60% and DTIL delivered -54.84% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.